Allergic Rhinitis Market Forecast

Datamonitor, December 2010

2009 allergic rhinitis sales are estimated at $5 billion in the seven major markets, and a decline to $4 billion is forecast by 2019. The greatest threat to the market is generics, with drug classes having differing vulnerability to generic erosion. While the symptomatic treatment sales will decrease, immunotherapy sales are on the rise, with changing regulations dictating development

Reasons to Purchase

- Understand allergic rhinitis market trends, including life cycle management, current sales, and a 10 year sales forecast of symptomatic treatments
- Gain insight into the immunotherapy market and access patient based forecasts of three key immunotherapy products, with interactive assumptions
- Assess analysis of key companies in the market and see how allergic rhinitis contributes to total brand sales

Introduction
Scope of this research
Research and analysis highlights
Key reasons to read this report

Forecasting Methodology
- The forecasting model
- General event information
- Event selection and quantification
- Event parameters

Customers who bought this item also bought

• Pipeline and Commercial Insight: Allergic Rhinitis - Immunotherapy Growth Surpassed by Generic Erosion
• Prescribing Influences: Allergic Rhinitis - Treatment tolerability remains a key differentiator
• Product Profiles: Allergic Rhinitis - Heavily Genericized Market sees Areas of Innovation
• R&D Trends: Allergic Rhinitis - Immunotherapy takes a rising share of the pipeline
• Epidemiology: Allergic Rhinitis - Allergic rhinitis is highly prevalent yet significantly under-diagnosed
• The Asthma, COPD & Allergic Rhinitis Market Outlook to 2016
• Emerging Opportunities in Inhalation & Nasal Spray Generic Drugs 2010
• Prostate Cancer (Event Driven)
• Physician and Payer Insights on the Impact of Emerging Therapies and Generic Donepezil on the U.S. Alzheimer's Disease Market
• Emerging Medical Technologies Spotlight